The FDA has directed manufacturers to remove B/Yamagata from influenza vaccines
CSL Seqirus is prepared for this change and will be bringing our full portfolio of influenza vaccines to the US market as trivalent formulations for the 2024-2025 season.
Everything you need to simplify your vaccination business
flu360® partners you with true flu professionals and solutions. Create an account to get started.
Built to help your clinic or network overcome challenges both unique and common.
Discover influenza vaccine technologies, access vaccine expertise, and download clinic tools and resources.
Understand financial status, and manage invoices and payment methods.
Place and track orders while managing inventory and overall performance.
We're here to strengthen and support your flu vaccination efforts
CSL Seqirus understands the complexities of managing flu vaccinations. When you sign up with flu360, you gain a dedicated partner, expert vaccination support and service, and access to CSL Seqirus' differentiated flu vaccine portfolio.
Explore the CSL Seqirus Vaccine Portfolio
Please see Important Safety Information and full US Prescribing Information on each vaccine's respective product page.
Access Featured Resources